• Blog
  • Overt Hepatic Encephalopathy Market Growth Analysis | 2023-2028

    Overt Hepatic Encephalopathy Market Growth Analysis | 2023-2028

    Overt Hepatic Encephalopathy Market Growth Analysis | 2023-2028
    Report code - SRHL277 Delivery - 2 Weeks
    Overt Hepatic Encephalopathy Market Size, Share, Trends, Dynamics, Growth, and Foreca See more...

    Market Insights

    The Overt Hepatic Encephalopathy Market was estimated at USD 87.8 million in 2022 and is likely to grow at a CAGR of 10.67% during 2023-2028 to reach USD 161.73 million in 2028.

    Overt-Hepatic-Encephalopathy-Market-Insights

    Wish to receive more information about this study? Click here to get a free sample.

    What is overt hepatic encephalopathy?

    Hepatic encephalopathy is a brain disorder that most commonly occurs in people having chronic liver disease. Its complications could be dysfunction of the brain and may include impaired memory, intellectual impairment, personality changes, and loss of consciousness (coma). Overt hepatic encephalopathy is associated with obvious, outward signs and symptoms in the affected individuals.

    COVID-19 Impact on Global Market

    The COVID-19 outbreak is projected to have a long-term impact on the growth of overt hepatic encephalopathy as people suffering from cirrhosis disease require intense preventive care which was affected by the spread of coronavirus. It affected the process developed to provide good care to the patients.

    Overt Hepatic Encephalopathy Market Highlights

    Market Size in 2022

    USD 87.8 million

    Market Size in 2028

    USD 161.73 million

    Market Growth (2023-2028)

    10.67% CAGR

    Base Year of Study

    2022

    Trend Period

    2017-2021

    Forecast Period

    2023-2028

    Key Players

    Key players operating in the global market are-

    • Alfa Wassermann S.P.A (Italy),
    • Rebiotix Inc. (The U.S),
    • Cosmo Pharmaceuticals S.P.A (Italy),
    • Spherium Biomed S.L (Spain),
    • Horizon Pharma Plc (Ireland),
    • Umecrine Cognition AB (Sweden),
    • Ocera Therapeutics Inc. (The U.S),
    • Mallinckrodt Pharmaceuticals (UK),
    • Kannalife Sciences Inc. (The U.S),
    • Bausch Health Companies Inc. (The U.S),
    • ASKA Pharmaceutical Co., Ltd (Japan),
    • Norgine BV (Netherlands).

    Market Dynamics

    The growth of the global market is primarily driven by the rising number of people having cirrhosis disease.

    • Cirrhosis is a chronic liver damage illness that can result in scarring and liver failure.
    • Increasing consumption of alcohol has resulted in an increased incidence of liver disease among people.
    • This further can lead to overt hepatic encephalopathy illness and thus, drive the market growth.
    • Growing emphasis on the development of advanced solutions by the market players is likely to propel the market growth at a significant rate during the review period.

    Overt-Hepatic-Encephalopathy-Market-Dynamics

    Want to have a closer look at this report, Download a free sample

    Segment Analysis

    Treatment Type

    Based on treatment, the market has been segmented into lactulose, antibiotics, probiotics, liver transplantation, and others. The lactulose segment accounted for the largest market share in 2022. The segment growth can be attributed to its ability to reduce ammonia production in the intestine by creating an aggressive for the bad microbes in the intestine.

    Regional Insights

    Geographically, the market in North America accounted for the largest market share in 2022 and is expected to continue its dominance over the forecast period owing to an increasing number of people suffering from cirrhosis. For instance, around 5.5 million people in the U.S. are affected by cirrhosis and approximately 70% of them are likely to develop symptoms of overt hepatic encephalopathy. The market in the Asia-Pacific region is projected to register the fastest growth during the review period on account of the rising number of people suffering from chronic liver diseases.

    Overt-Hepatic-Encephalopathy-Market-Regional-Insights

    Want to know which region offers the best growth opportunities then, Click Here.

    Critical Questions Answered in the Report

    • What are the key trends in the global market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the global market?
    • What are the key strategies adopted by the major vendors to lead in the global market?
    • What is the market share of the top vendors?

    Market Segmentation

    This report studies the market covering a period of 12 years of trend and forecast. The report provides detailed insights into the market dynamics to enable informed business decision-making and growth strategy formulation based on the opportunities present in the market.

    The market is segmented into the following categories.

    By Disease Severity Type

    • Type A
    • Type B
    • Type C

    By Diagnosis Type

    • Blood Tests
    • Liver Function Test
    • Encephalogram
    • Other

    By Treatment Type

    • Lactulose
    • Antibiotics
    • Probiotics
    • Liver Transplantation
    • Other

    By End User Type

    • Hospitals & Clinics
    • Research Institutes
    • Surgical Centers
    • Other

    By Region

    • North America (Country Analysis: the USA, Canada, and Mexico)
    • Europe (Country Analysis: Germany, France, the UK, Russia, Spain, and the Rest of Europe)
    • Asia-Pacific (Country Analysis: China, Japan, India, South Korea, and the Rest of Asia-Pacific)
    • Rest of the World (Sub-Region Analysis: Latin America, the Middle East, and Others)

    Overt-Hepatic-Encephalopathy-Market-Segmentation

    Want to know the most attractive market segments? Register Here

    Target Audience

    Here is the list of the group of customers that the Global Market hopes to have the greatest opportunity to convert-

    • Overt hepatic encephalopathy manufacturers
    • Overt hepatic encephalopathy suppliers
    • Overt hepatic encephalopathy distributors
    • Organizations
    • Government bodies

    Research Methodology

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.

    More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data.

    We conducted more than 10 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.

    Report Features

    This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

    What Deliverables Will You Get in this Report?

    Key questions this report answers

    Relevant contents in the report

    How big is the sales opportunity?

    In-depth Analysis of the Overt Hepatic Encephalopathy Market

    How lucrative is the future?

    Market forecast and trend data and emerging trends

    Which regions offer the best sales opportunities?

    Global, regional, and country-level historical data and forecasts

    Which are the most attractive market segments?

    Market Segment Analysis and Forecast

    Which are the top players and their market positioning?

    Competitive landscape analysis, Market share analysis

    How complex is the business environment?

    Porter’s five forces analysis, PEST analysis, Life cycle analysis

    What are the factors affecting the market?

    Drivers & challenges

    Will I get the information on my specific requirements?

    10% free customization

    Report Customization Options

    With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

    Company Profiling

    • Detailed profiling of additional market players (up to 3 players)
    • SWOT analysis of key players (up to 3 players)

    Market Segmentation

    • Current market segmentation by any one of the disease severity types by treatment type.

    Competitive Benchmarking

    • Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

    Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    Hepatic encephalopathy is a brain disorder that most commonly occurs in people having chronic liver disease. Its complications could be dysfunction of the brain and may include impaired memory, intellectual impairment, personality changes, and loss of consciousness (coma). Overt hepatic encephalopathy is associated with obvious, outward signs and symptoms in the affected individuals.

    The overt hepatic encephalopathy market size is expected to reach USD 161.73 million in the foreseeable future.

    The overt hepatic encephalopathy market is expected to witness an impressive growth of 10.67% CAGR in the foreseeable future.

    Alfa Wassermann S.P.A (Italy), Rebiotix Inc. (The U.S), Cosmo Pharmaceuticals S.P.A (Italy), Spherium Biomed S.L (Spain), Horizon Pharma Plc (Ireland), Umecrine Cognition AB (Sweden), Ocera Therapeutics Inc. (The U.S), Mallinckrodt Pharmaceuticals (UK), Kannalife Sciences Inc. (The U.S), Bausch Health Companies Inc. (The U.S), ASKA Pharmaceutical Co., Ltd (Japan) and Norgine BV (Netherlands) are among the key players in the market.

    North America is expected to remain dominant in the market during the forecast period.

    Asia-pacific is expected to register the fastest growth in the market in the coming years.

    The lactulose segment accounted for the largest share in the market in 2022.

    Overt hepatic encephalopathy manufacturers, Overt hepatic encephalopathy suppliers, Overt hepatic encephalopathy distributors, Organizations, Government bodies are the target audience in the market.